Current and Future Perspectives of Combining Chemotherapy and Stereotactic Body Radiation Therapy with Immunotherapy in the Treatment of Lung Cancer-Reference-Cited by-同舟云学术

Current and Future Perspectives of Combining Chemotherapy and Stereotactic Body Radiation Therapy with Immunotherapy in the Treatment of Lung Cancer

Published:2024 Issue: Volume: Page:265-295
ISSN:
Container-title:Immunotherapy Against Lung Cancer
language:en
Short-container-title:

Author:

Krishna Abhishek,Saldanha Elroy,Marakala Vijay,Simon Paul,George Thomas,Anthony Raymond,Prabhakar Pankaj,Palatty Princy Louis,Baliga Manjeshwar Shrinath

Publisher

Springer Nature Singapore

Link

https://link.springer.com/content/pdf/10.1007/978-981-99-7141-1_14

Reference119 articles.

1. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ (2001) ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94:774–782

2. Anscher MS, Arora S, Weinstock C, Amatya A, Bandaru P, Tang C, Girvin AT, Fiero MH, Tang S, Lubitz R, Amiri- Kordestani L, Theoret MR, Pazdur R, Beaver JA (2022) Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration database. JAMA Oncol 8(2):232–240. https://doi.org/10.1001/jamaoncol.2021.6439

3. Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

4. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–857

5. Bassanelli M, Ramella S, Zeuli M, Ceribelli A (2022) Radiotherapy and immunotherapy: the power of the teamwork for the treatment of NSCLC. Anticancer Res 42(5):2241–2247